Tel:025-68136891, 17366374446  

Sign in  |  Register
中文  English
Location:Home » Education » Tutorial Introduction » Gao Wentao
Gao Wentao

Gao Wentao is a chief physician, associate professor and master supervisor. He currently works as the Deputy Director of Pancreas Research Institute of Nanjing Medical University, the member and Secretary of Pancreas Group of Jiangsu Branch of Chinese Medical Association, the member of Minimally Invasive Treatment for Pancreatic Cancer(MITPC) of Chinese Anti-Cancer Association, Fellow of International College of Surgeons. He is also a key medical talent for Jiangsu Province, a key talent of "Thirteenth Five-year Plan" of Jiangsu Province, and "Jiangsu Outstanding Health Talent".

Won the 2011 Ministry of Education Award for Scientific and Technological Progress as a main contributor (“The Foundation and Clinical Study of Pancreatic Cancer”, ranked the fourth); “The Occurrence Mechanism and Development Mechanism and Clinical Technological Innovation Study of Pancreatic Cancer” won the Second Prize of 2015 China Award for Medical Scientific and Technological Progress (ranked the fourth); “The Innovation and Application of Key Medical Technologies of Pancreatic Cancer” won the First Prize of 2015 Jiangsu Provincial Prize for Science and Technology (ranked the fourth); “The Study of the Foundation and the Application of New Clinical Technology of Pancreatic Cancer” won the First Prize of 2015 Jiangsu Provincial Award for Medical Science and Technology (ranked the fourth).

Personnel programs and scientific research tasks involved

2016.01-2019.12. The person in charge of the Study of How VASH2 and PRMT5/KIF11 Proteins Decorate and Promote the Progression of Pancreatic Cancer as Mutually Regulatory Proteins, a project of Natural Science Foundation of China;

2014.01-2017.01. The person in charge of ChIP-Seq Analysis of the Tumor-Promoting Downstream Signal Path in VASH2 Gene of Pancreatic Cancer, a project of Natural Science Foundation of China;

2012.01-2015.12. The person in charge of the Exploration of the Effects of the Transcriptional Activation of VASH2 on the Generation of Hepatocellular Carcinoma Blood Vessels and the Effects and Mechanism of Epithelial-Mesenchymal Transition, a project of Natural Science Foundation of China;

2006.1-2008.12. The person in charge of the Design and Immune Study of the MUC4 Antigen Multi-Epitope DNA of Pancreatic Cancer, a project of Natural Science Foundation of China;

2012.01-2015.12. The person in charge of the Study of How the Epigenetic Mechanism in Pancreatic Cancer Promotes the Generation of Blood Vessels and EMT, a key project of Jiangsu Provincial Ministry of Health;

2009.1-2010.12. The person in charge of the MCA-Microarray Study of Abnormal DNA Methylation Table of Pancreatic Cancer, Nanjing Scientific and Technological Development Plan;

2004.01-2005.12. The person in charge of Screening/Decorating MUC Antigen Peptide to Improve the Immunization of Pancreatic Tumor, the Scientific and Technological Progress Fund of Nanjing Medical University.

Research Area

1)Epigenetics refers to a subject that studies the heritable changes of genetic expression under the circumstance that the nucleotide sequence of gene remains unchanged. It is one of the most active and frontier field of tumor studies. With screening method such as methylation microarrays, the research team was the first in the world that discovered VASH2 gene and micro RNA-615 have epigenetic alterations in pancreatic cancer and liver cancer where they act as important roles that promote and suppress the growth of tumors. The research results were reported in Oncogene, an authoritative journal, in 2013 and 2014. In current study, genes are used to knock out mice and cells, and Chromatin-IP and CO-IP are adopted to elaborate the direct mechanism of action. The study won three financial support programs of Natural Science Foundation of China, and published 8 SCI dissertations. 

2)Minimally invasive pancreatic operation: Pancreatic operation still remains one of the unconquered fields of minimally invasive operations. I have learned about minimally invasive pancreatic operation in Mayo Clinic in the US, and started promoting minimally invasive operations and laparoscopic surgery in the surgical segment of pancreas in China.


1.   WuJ, Guo F, Wei J, et al. [Surgical treatment for pancreatic neuroendocrineneoplasmas]. Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang UniversityMedical sciences 2016; 45(1): 31-5.

2.   WeiJ, Liu X, Wu J, et al. Diagnosis and surgical management of insulinomas in 33consecutive patients at a single institution. Langenbeck's archives of surgery2016; 401(7): 1019-25.

3.   TuM, Lu C, Lv N, et al. Vasohibin 2 promotes human luminal breast cancerangiogenesis in a non-paracrine manner via transcriptional activation offibroblast growth factor 2. Cancer letters 2016; 383(2): 272-81.

4.   LuZ, Yin J, Wei J, et al. Small amounts of tissue preserve pancreatic function:Long-term follow-up study of middle-segment preserving pancreatectomy. Medicine2016; 95(46): e5274.

5.   HuoX, Wei J, Liu X, et al. Brunner's gland cyst in combination withgastrointestinal stromal tumor: A case report. Oncology letters 2016; 11(5):3409-12.

6.   GaoW, Dai X, Dai C, et al. Comparison of patency rates and clinical impact ofdifferent reconstruction methods following portal/superior mesenteric veinresection during pancreatectomy. Pancreatology : official journal of theInternational Association of Pancreatology (IAP)  [et al] 2016; 16(6): 1113-23.

7.   WeiJ, Liu X, Wu J, et al. Modified One-layer Duct-to-mucosa PancreaticojejunostomyReduces Pancreatic Fistula After Pancreaticoduodenectomy. International surgery2015.

8.   GeQ, Zhou J, Tu M, et al. Nuclear vasohibin-2 promotes cell proliferation byinducing G0/G1 to S phase progression. Oncology reports 2015; 34(3): 1327-36.

9.   XueX, Zhang Y, Zhi Q, et al. MiR200-upregulated Vasohibin 2 promotes the malignanttransformation of tumors by inducing epithelial-mesenchymal transition inhepatocellular carcinoma. Cell communication and signaling : CCS 2014; 12: 62.

10. TuM, Liu X, Han B, et al. Vasohibin2 promotes proliferation in human breastcancer cells via upregulation of fibroblast growth factor2 andgrowth/differentiation factor15 expression. Molecular medicine reports 2014;10(2): 663-9.

11. MiaoY, Lin S, Gao W. [Surgical strategy for hemorrhagepost-pancreaticoduodenectomy]. Zhonghua wai ke za zhi [Chinese journal ofsurgery] 2014; 52(9): 647-50.

12. LiZ, Tu M, Han B, et al. Vasohibin 2 decreases the cisplatin sensitivity ofhepatocarcinoma cell line by downregulating p53. PloS one 2014; 9(3): e90358.

13. SunJ, Tu M, Han B, et al. Generation and characterization of rabbit polyclonalantibodies against Vasohibin-2 for determination of its intracellularlocalization. International journal of oncology 2013; 43(1): 255-61.

14. ChenJ, Li Q, An Y, et al. CEACAM6 induces epithelial-mesenchymal transition andmediates invasion and metastasis in pancreatic cancer. International journal ofoncology 2013; 43(3): 877-85.

15. AnY, Cai B, Chen J, et al. MAP3K10 promotes the proliferation and decreases thesensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 andGli-2. Cancer letters 2013; 329(2): 228-35.

16. ChenM, Xue X, Wang F, et al. Expression and promoter methylation analysis ofATP-binding cassette genes in pancreatic cancer. Oncology reports 2012; 27(1):265-9.

17. XueX, Lu Z, Tang D, et al. Galectin-1 secreted by activated stellate cells inpancreatic ductal adenocarcinoma stroma promotes proliferation and invasion ofpancreatic cancer cells: an in vitro study on the microenvironment ofpancreatic ductal adenocarcinoma. Pancreas 2011; 40(6): 832-9.

18. ZhuZ, Gao W, Qian Z, Miao Y. Genetic variation of miRNA sequence in pancreaticcancer. Acta biochimica et biophysica Sinica 2009; 41(5): 407-13.

19. WuJ, Wei J, Meng K, et al. Identification of an HLA-A*0201-restrictive CTLepitope from MUC4 for applicable vaccine therapy. Immunopharmacology andimmunotoxicology 2009; 31(3): 468-76.

20. WeiJ, Gao W, Wu J, et al. Dendritic cells expressing a combined PADRE/MUC4-derivedpolyepitope DNA vaccine induce multiple cytotoxic T-cell responses. Cancerbiotherapy & radiopharmaceuticals 2008; 23(1): 121-8.

21. GaoW, Kondo Y, Shen L, et al. Variable DNA methylation patterns associated withprogression of disease in hepatocellular carcinomas. Carcinogenesis 2008;29(10): 1901-10.